Genmab A/S(Nasdaq:GMAB)today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cellengaging antibody administered subcutaneously, ...
Pour one out for AOL dial-up, Windows 10, and a host of other tech gadgets and services that powered down and logged off this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback